Breaking News Instant updates and real-time market news.

TEVA

Teva

$6.70

0.29 (4.52%)

, ATRS

Antares Pharma

$3.12

-0.015 (-0.48%)

08:24
08/20/19
08/20
08:24
08/20/19
08:24

Teva announces availability of EpiPen Jr generic equivalent

Teva (TEVA) announced availability of the FDA-approved generic version of EpiPen Jr auto-injector, 0.15 mg, in the U.S. The product is available in most retail pharmacies, and the wholesale acquisition Cost is $3002 for a 2-pack. Currently, one in nine generic prescriptions dispensed in the U.S. is filled with a Teva product. Teva's generic equivalent of EpiPen and EpiPen Jr utilize the Antares Pharma (ATRS) Vibex device. Antares and Teva have an exclusive license, development and supply agreement for epinephrine auto injector products that Teva markets in the U.S.

TEVA

Teva

$6.70

0.29 (4.52%)

ATRS

Antares Pharma

$3.12

-0.015 (-0.48%)

  • 11

    Sep

TEVA Teva
$6.70

0.29 (4.52%)

08/07/19
EVER
08/07/19
DOWNGRADE
EVER
In Line
Teva downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat downgraded Teva to In Line from Outperform.
08/07/19
EVER
08/07/19
DOWNGRADE
EVER
In Line
Evercore ISI sees 'lots more uncertainty' at Teva, downgrades to In Line
As previously reported, Evercore ISI analyst Umer Raffat downgraded Teva to In Line from Outperform in light of new disclosures today that he believes "have introduced lots more uncertainty." The company's cash flows "have been a HUGE issue," its debt maturities "haven't been managed properly," the opioid litigation situation is getting more unclear and its CFO is departing, said Raffat, who removed his price target Teva shares.
08/08/19
RAJA
08/08/19
NO CHANGE
Target $15
RAJA
Outperform
Teva price target lowered to $15 from $22 at Raymond James
Raymond James analyst Elliot Wilbur lowered his price target for Teva Pharmaceutical to $15 from $22 but maintained an Outperform rating following the company's quarterly results. While Teva's shares continue to struggle to locate a bottom, Wilbur tells investors in a research note that "the song remains the same on fundamentals hummed to the tune of stability." A return to at least modest growth in 2020 and beyond appears highly likely at this juncture with U.S. generics on the rebound, he adds. Wilbur says he continues to see upside scenarios in Teva shares over the next 12-18 months given bottom in U.S. generics, further signs the Copaxone hole will be by new brand launches and further potential quantification around opioid liabilities emerges.
08/08/19
RHCO
08/08/19
NO CHANGE
Target $7
RHCO
Hold
Teva price target lowered to $7 from $10 at SunTrust
SunTrust analyst Gregg Gilbert lowered his price target on Teva to $7 and kept his Hold rating in spite of its Q2 earnings beat. The analyst says the quarter was decent with "continued stability" seen in North America generics, but he is concerned about the perception of the departure of Teva's CEO. Gilbert also points to Teva becoming the first company in his coverage to reserve a sum for potential opioid settlements.
ATRS Antares Pharma
$3.12

-0.015 (-0.48%)

11/06/18
JEFF
11/06/18
NO CHANGE
Target $8
JEFF
Buy
Antares Pharma price target raised to $8 from $7 at Jefferies
Jefferies analyst Anthony Petrone raised his price target on Antares Pharma shares to $8 from $7 following the company's Q3 report and operating update. Petrone keeps a Buy rating on Antares shares, which are up 3c, or 1%, to $3.53 in afternoon trading.
02/22/19
JEFF
02/22/19
NO CHANGE
Target $8
JEFF
Buy
Antares Pharma upside share target raised to $18-$20 at Jefferies
Jefferies analyst Anthony Petrone's revised sum-of-the-parts analysis on Antares Pharma continues to assign a current risk-adjusted value of $8 per share. However, it ow sees upside to $18-$20, versus $15 prior, based on "strong initial feedback" on Xyosted, "longer tailwind" for Makena, larger opportunity for generic EpiPen given ongoing shortages, and earlier potential launch of generic Forteo. Early feedback from physicians and patients is positive and continues to support that 20% share capture is feasible for Xyosted over time, Petrone tells investors in a research note. He keeps a Buy rating on Antares Pharma.
02/25/19
COWN
02/25/19
INITIATION
Target $7
COWN
Outperform
Antares Pharma initiated with an Outperform at Cowen
Cowen analyst Bill Maughan initiated Antares Pharma with an Outperform rating as he sees it as the pre-eminent auto-injector developer, while almost near the break-even point due to its meaningful partnerships. He said its durable revenue base has created a self-sustaining company. Maughan has a $7 price target on Antares Pharma shares.
02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CRSP

Crispr Therapeutics

$49.70

2.08 (4.37%)

07:09
09/17/19
09/17
07:09
09/17/19
07:09
Hot Stocks
Crispr Therapeutics, ViaCyte present data from regenerative medicine program »

CRISPR Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATU

Actuant

$26.23

0.03 (0.11%)

07:09
09/17/19
09/17
07:09
09/17/19
07:09
Downgrade
Actuant rating change  »

Actuant downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AAPL

Apple

$219.88

1.17 (0.53%)

, GLW

Corning

$30.04

-0.12 (-0.40%)

07:07
09/17/19
09/17
07:07
09/17/19
07:07
Hot Stocks
Apple awards additional $250M to Corning for glass processes »

Apple (AAPL) announced it…

AAPL

Apple

$219.88

1.17 (0.53%)

GLW

Corning

$30.04

-0.12 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIR

Circor

$37.27

0.29 (0.78%)

07:06
09/17/19
09/17
07:06
09/17/19
07:06
Upgrade
Circor rating change  »

Circor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

APLT

Applied Therapeutics

$9.20

-0.5 (-5.15%)

07:05
09/17/19
09/17
07:05
09/17/19
07:05
Hot Stocks
Applied Therapeutics to present data highlighting AT-001 at EASD meeting »

Applied Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAPR

Capricor Therapeutics

$2.70

-0.03 (-1.10%)

07:03
09/17/19
09/17
07:03
09/17/19
07:03
Hot Stocks
Capricor Therapeutics to present results from HOPE-2 trial of CAP-1002 in DMD »

Capricor Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$77.17

0.58 (0.76%)

07:03
09/17/19
09/17
07:03
09/17/19
07:03
Upgrade
Ameren rating change  »

BofA/Merrill upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 10

    Nov

CNPOF

Canopy Rivers

$0.00

(0.00%)

07:02
09/17/19
09/17
07:02
09/17/19
07:02
Hot Stocks
Canopy Rivers' TerrAscend enters distribution agreement with Syqe Medical »

Canopy Rivers is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBNC

Reliant Bancorp

$24.70

0.16 (0.65%)

07:02
09/17/19
09/17
07:02
09/17/19
07:02
Conference/Events
Reliant Bancorp to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

LPTX

Leap Therapeutics

$1.81

0.035 (1.97%)

07:02
09/17/19
09/17
07:02
09/17/19
07:02
Hot Stocks
Leap Therapeutics announces update on Phase 2 clinical trial of DKN-01 »

Leap Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AAPL

Apple

$219.88

1.17 (0.53%)

07:01
09/17/19
09/17
07:01
09/17/19
07:01
Periodicals
Apple challanges $14B tax charge from European Commission, CNBC reports »

Apple has challenged a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$15.76

-0.24 (-1.50%)

, FB

Facebook

$186.24

-0.73 (-0.39%)

07:00
09/17/19
09/17
07:00
09/17/19
07:00
Upgrade
Susquehanna upgrades Snap to Neutral after positive advertising checks »

Susquehanna analyst Shyam…

SNAP

Snap

$15.76

-0.24 (-1.50%)

FB

Facebook

$186.24

-0.73 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

MDR

McDermott

$6.08

0.28 (4.83%)

06:58
09/17/19
09/17
06:58
09/17/19
06:58
Hot Stocks
McDermott joint venture awarded module fabrication contract »

McDermott announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

AEE

Ameren

$77.17

0.58 (0.76%)

06:57
09/17/19
09/17
06:57
09/17/19
06:57
Upgrade
Ameren rating change  »

Ameren upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 10

    Nov

MCFT

MasterCraft Boat Holdings

$14.41

-0.1 (-0.69%)

06:55
09/17/19
09/17
06:55
09/17/19
06:55
Conference/Events
MasterCraft Boat Holdings to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

OSMT

Osmotica Pharmaceuticals

$3.84

0.15 (4.07%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Hot Stocks
Osmotica subsidiary submits NDA to FDA for RVL-1201 »

Vertical Pharmaceuticals,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAST

Eastside Distilling

$4.97

-0.03 (-0.60%)

06:51
09/17/19
09/17
06:51
09/17/19
06:51
Conference/Events
Eastside Distilling to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

, SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Alliance Data signs agreement to provide credit card services for Sally Beauty »

Alliance Data (ADS) has…

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

KAMN

Kaman

$63.22

0.55 (0.88%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Kaman awarded $42M order of Joint Programmable Fuzes »

Kaman announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZYME

Zymeworks

$25.84

0.19 (0.74%)

06:49
09/17/19
09/17
06:49
09/17/19
06:49
Hot Stocks
Zymeworks names Lota Zoth as board Chair, voluntarily delists from TSX »

Zymeworks announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

, ADS

Alliance Data

$132.88

-1.11 (-0.83%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Sally Beauty signs agreement with Alliance Data's card services business »

Sally Beauty Holdings…

SBH

Sally Beauty

$14.47

-0.12 (-0.82%)

ADS

Alliance Data

$132.88

-1.11 (-0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

  • 13

    Nov

  • 03

    Dec

MRK

Merck

$82.01

-0.6 (-0.73%)

06:47
09/17/19
09/17
06:47
09/17/19
06:47
Hot Stocks
Merck: FDA accepts BLA, grants priority review for investigational Ebola vaccine »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

XLRN

Acceleron

$44.67

0.75 (1.71%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Recommendations
Acceleron analyst commentary  »

Acceleron should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGOV

NIC Inc.

$21.79

0.05 (0.23%)

06:40
09/17/19
09/17
06:40
09/17/19
06:40
Downgrade
NIC Inc. rating change  »

NIC Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.